Donor mesenchymal stem cell linetics after transamniotic stem cell therapy (TRASCET) for experimental spina bifida
- 1 June 2018
- journal article
- conference paper
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 53 (6) , 1134-1136
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- A comparison between placental and amniotic mesenchymal stem cells for transamniotic stem cell therapy (TRASCET) in experimental spina bifidaJournal of Pediatric Surgery, 2016
- Trans-amniotic stem cell therapy (TRASCET) minimizes Chiari-II malformation in experimental spina bifidaJournal of Pediatric Surgery, 2015
- Plexin-B1 signalling promotes androgen receptor translocation to the nucleusOncogene, 2015
- Partial or complete coverage of experimental spina bifida by simple intra-amniotic injection of concentrated amniotic mesenchymal stem cellsJournal of Pediatric Surgery, 2015
- Amniotic Mesenchymal Stem Cells Enhance Normal Fetal Wound HealingStem Cells and Development, 2011
- A Randomized Trial of Prenatal versus Postnatal Repair of MyelomeningoceleNew England Journal of Medicine, 2011
- Amniotic and Placental Mesenchymal Stem Cell Isolation and Culture2011
- Engraftment, Differentiation, and Functional Benefits of Autologous Cardiosphere-Derived Cells in Porcine Ischemic CardiomyopathyCirculation, 2009
- Retinoic acid induced myelomeningocele in fetal rats: Characterization by histopathological analysis and magnetic resonance imagingExperimental Neurology, 2005
- The amniotic fluid as a source of cells for fetal tissue engineeringJournal of Pediatric Surgery, 2001